This in vitro observation is supported by a small sample (33) of patients from a phase II study of sorafenib [7] and a slightly larger number (54) of patients in a retrospective clinical study [8], whose clinical benefits are associated with high pERK staining in their tumor samples. Here, EIF2AK3 is linked to neoplasm.